Drugs / ALSEVALIMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03514121 | Mar 2018 → Apr 2021 | breast cancer, endometrial cancer, ovarian cancer | Five Prime Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALSEVALIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594545 ↗ |
| Known as | FPA150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03514121 ↗ |
| Modality | Monoclonal antibody | “A monoclonal antibody against B7-H4” NCT03514121 ↗ |